SynthesisEuropean journal of trauma and emergency surgery : official publication of the European Trauma Society2026
Assessing the role of REBOA in the management of hemodynamically unstable pelvic fractures: a systematic review and meta-analysis.
Synthesis in European journal of trauma and emergency surgery : official publication of the European Trauma Society, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
purposeThe role of zone III resuscitative endovascular balloon occlusion of the aorta (REBOA) in the management of hemodynamically unstable pelvic fractures remains controversial, with conflicting evidence regarding its impact on mortality and a lack of consensus on optimal treatment strategies. The aim of this systematic review was to assess the impact of the addition of zone III REBOA alongside conventional treatment modalities.
methodPubMed, Embase, Scopus and the Cochrane Library were systematically searched on October 2024 and December 2025. Primary outcomes included in-hospital mortality, mortality within 24 h and post-24-hour mortality. Data was pooled using a random-effects model. Outcomes are reported as risk ratios (RR) or mean difference (MD) with 95 per cent confidence intervals. The risk of bias was assessed using the Newcastle-Ottawa Scale (NOS).
resultsA total of seven retrospective cohort studies were included, representing a total of 837 patients (REBOA: 343, non-REBOA: 494). REBOA use was associated with significantly higher in-hospital mortality (RR 1.44, 95% CI 1.13–1.78; p = 0.0006) and higher 24-hour mortality (RR 1.90, 95% CI 1.13–3.20; p = 0.0292). Mortality beyond 24 h did not differ significantly between groups (RR 1.30, 95% CI 0.55–3.04; p = 0.4).
conclusionIn patients with hemodynamically unstable pelvic fractures, zone III REBOA is associated with increased early and overall in-hospital mortality and substantially higher early transfusion requirements, without demonstrable benefit in complications or length of stay. Given the limited certainty of evidence from retrospective studies, further prospective investigations are needed to better clarify the role of zone III REBOA.
Indexed as
Identifiers
41697361What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.